Real-Time, Ultrasensitive, and High-Throughput Monitoring of Adeno-Associated Virus Production via an Aldehyde-Functionalized Dual-Capture MetaSPR Fishing Sensor

share:

Brief intro:

  • Author: Hanlin Zhou, Youqian Chen, Tong Li, Yuhong Li, Jie Li, Yanan Li, Xianchun Zong, Gang Logan Liu, Zhiguo Qin, Liping Huang
  • Journal: Analytical Chemistry
  • Doi: https://www.doi.org/10.1021/acs.analchem.5c07077
  • Publication Date: 2026/1/20

Products/Services used in the paper

Request Quote

Abstract

Adeno-associated virus (AAV) is a key vector in gene therapy, yet conventional AAV quality control methods are time-consuming and unsuitable for real-time monitoring, severely hindering process optimization. Here, we present an aldehyde-functionalized metasurface plasmon resonance (ALMetaSPR) biosensor for rapid, label-free, and high-throughput AAV quantification. Two complementary platforms were developed: a 96-well high-throughput system enabling analysis within 15 min (8-fold faster than ELISA); and a portable MetaSPR-based process analytical technology (PAT) device (MSPR-PAT) that integrates microfluidics and smartphone interfaces for real-time online monitoring of AAV production. Both platforms can accurately quantify AAV-2 and AAV-5 titers directly without sample labeling. The antibody-based capture system exhibited a broad dynamic range (6.25 × 1009–4.00 × 1011 GC/mL) with a limit of detection (LOD) of 1.24 × 1009 GC/mL, representing a 250-fold sensitivity improvement over current label-free techniques. The biosensor surface can be regenerated more than 42 cycles without performance loss, which significantly reduces the per-test costs. This innovation resolves a critical bottleneck in gene-therapy manufacturing by integrating high-throughput screening, real-time process analytics, and one-step operation.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download

Login

Don't have an account? Please register
Account*
Password*
Code*
Refresh
Forgot password?
Logging in indicates that you have read and accepted the Registration Agreement and User Agreement
Log in with other accounts

New User Registration

Already have an account?
First Name*
Middle Name
Last Name*
Organization*
Organization Type*
Country/State*
Email Address*
Set Password*
Confirm password*
Refferal Code*

Reset Password

Return to
Email*
Code*
New password*
Confirm password*

Google Account Binding

Organization*
Organization Type*
Country/State*